Published by Coherent Market Insights
Posted on September 28, 2021
Celiac Disease Drugs Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Celiac Disease Drugs Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/168
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation, ImmusanT, and the Institute for Protein Design.
Celiac disease is an autoimmune disorder that cause damage and inflammation to the small intestine and mostly found in people who are hereditarily inclined towards gluten. Some of the symptoms of celiac disease are gastrointestinal malfunctions such as diarrhea, abdominal distention, loss of appetite, and among kids’ failure to grow normally and also sometimes loss of lymphocytes. Coeliac disease is triggered when the body reacts to gluten, generally found in wheat and in other grains such as barley and rye.
100% gluten-free diet is the only existing treatment for celiac disease
According to the National Foundation for Celiac Awareness (NFCA), celiac disease affects both men and women of all age groups and races. It is estimated that around 83% of all local Americans who have celiac disease are untreated or misdiagnosed with other bowel disorders. People with untreated celiac disease incur additional average medical costs of US$ 3,964 as compared to healthy individuals. Of all the people diagnosed with celiac disease, 5-22% have an immediate family member who was diagnosed with celiac disease. There are no specific drugs to treat celiac diseases. The total number of individuals diagnosed in the U.K. with celiac disease has increased fourfold between 1990 and 2011, from 5.2 per 100,000 to 19.1 per 100,000. This inadvertently creates a highly conducive environment for the growth of the celiac disease drugs market, once such a drug is commercialized in the market.
Bowel biopsy the only available method to confirm celiac disease: current scenario of the market
The celiac disease drugs are still undergoing clinical trials as it is difficult to identify celiac disease in the primary stages, because the symptoms are deceptively similar to those of other bowel disorders. Various subtle and selective blood tests such as anti-tissue transglutaminase antibodies are used to screen the disease. If the test results are positive, then the individual is asked to undergo a small bowel biopsy to confirm the disease, as there is no specific or defined treatment. Nevertheless, extensive R&D activities are currently underway are expected to pave way for more effective and advanced diagnostic options and innovative drugs, which is expected to position the global celiac disease drugs market on a high growth trajectory.
Celiac Disease Drugs Market Outlook: A sea of opportunity beckons
Regional segmentation by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the University of Chicago Medicine, Celiac Disease Center, approximately 1% of healthy average Americans are affected by celiac disease. In 2007, 3 million individuals were affected with Celiac Disease and 97% of people are undiagnosed and untreated. Around 3 million people were suffering from diabetes type1, out of which 6% (180,000) also had celiac disease; around 610,000 unexplained infertility cases were reported, out of which 6% also suffered from celiac disease. The prevalence of the celiac disease in the U.S. in healthy people is 1 in 133 and is estimated at 1 in 56 in people with related symptoms. People with first degree and second-degree relatives suffering from celiac disease are 1 in 22 and 1 in 39, respectively. This creates highly lucrative growth opportunities for players in the global celiac disease drugs market, post clinical trial approval. The Asia Pacific is likely to show high growth rates in the year’s post-drug approval in the global celiac disease drugs industry, with China and India being the highest revenue contributors. On the other side, strict regulatory frameworks for drug approval are expected to hamper the market growth.
Buy This Premium Report Of Celiac Disease Drugs Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/168
In this study, the years considered to estimate the market size of Celiac Disease Drugs are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Celiac Disease Drugs Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Celiac Disease Drugs Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Celiac Disease Drugs Market With The Market Scenario, Distinguishing Regions, And Key Players Such As Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation appeared first on Gatorledger.
Celiac Disease Drugs Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Celiac Disease Drugs Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/168
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation, ImmusanT, and the Institute for Protein Design.
Celiac disease is an autoimmune disorder that cause damage and inflammation to the small intestine and mostly found in people who are hereditarily inclined towards gluten. Some of the symptoms of celiac disease are gastrointestinal malfunctions such as diarrhea, abdominal distention, loss of appetite, and among kids’ failure to grow normally and also sometimes loss of lymphocytes. Coeliac disease is triggered when the body reacts to gluten, generally found in wheat and in other grains such as barley and rye.
100% gluten-free diet is the only existing treatment for celiac disease
According to the National Foundation for Celiac Awareness (NFCA), celiac disease affects both men and women of all age groups and races. It is estimated that around 83% of all local Americans who have celiac disease are untreated or misdiagnosed with other bowel disorders. People with untreated celiac disease incur additional average medical costs of US$ 3,964 as compared to healthy individuals. Of all the people diagnosed with celiac disease, 5-22% have an immediate family member who was diagnosed with celiac disease. There are no specific drugs to treat celiac diseases. The total number of individuals diagnosed in the U.K. with celiac disease has increased fourfold between 1990 and 2011, from 5.2 per 100,000 to 19.1 per 100,000. This inadvertently creates a highly conducive environment for the growth of the celiac disease drugs market, once such a drug is commercialized in the market.
Bowel biopsy the only available method to confirm celiac disease: current scenario of the market
The celiac disease drugs are still undergoing clinical trials as it is difficult to identify celiac disease in the primary stages, because the symptoms are deceptively similar to those of other bowel disorders. Various subtle and selective blood tests such as anti-tissue transglutaminase antibodies are used to screen the disease. If the test results are positive, then the individual is asked to undergo a small bowel biopsy to confirm the disease, as there is no specific or defined treatment. Nevertheless, extensive R&D activities are currently underway are expected to pave way for more effective and advanced diagnostic options and innovative drugs, which is expected to position the global celiac disease drugs market on a high growth trajectory.
Celiac Disease Drugs Market Outlook: A sea of opportunity beckons
Regional segmentation by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the University of Chicago Medicine, Celiac Disease Center, approximately 1% of healthy average Americans are affected by celiac disease. In 2007, 3 million individuals were affected with Celiac Disease and 97% of people are undiagnosed and untreated. Around 3 million people were suffering from diabetes type1, out of which 6% (180,000) also had celiac disease; around 610,000 unexplained infertility cases were reported, out of which 6% also suffered from celiac disease. The prevalence of the celiac disease in the U.S. in healthy people is 1 in 133 and is estimated at 1 in 56 in people with related symptoms. People with first degree and second-degree relatives suffering from celiac disease are 1 in 22 and 1 in 39, respectively. This creates highly lucrative growth opportunities for players in the global celiac disease drugs market, post clinical trial approval. The Asia Pacific is likely to show high growth rates in the year’s post-drug approval in the global celiac disease drugs industry, with China and India being the highest revenue contributors. On the other side, strict regulatory frameworks for drug approval are expected to hamper the market growth.
Buy This Premium Report Of Celiac Disease Drugs Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/168
In this study, the years considered to estimate the market size of Celiac Disease Drugs are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Celiac Disease Drugs Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Celiac Disease Drugs Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Celiac Disease Drugs Market With The Market Scenario, Distinguishing Regions, And Key Players Such As Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation appeared first on Gatorledger.
Explore more articles in the Research Reports category
